Development of monoclonal antibodies for therapeutic drug monitoring.
For the development of multilayer fluorescent immunoassays to determine directly a variety of therapeutic drugs high specific monoclonal antibodies against the anticonvulsants carbamazepine, phenobarbital, phenytoin and valproic acid have been prepared. For each antibody a standard curve could be established showing good linearity and a suitable sensitivity scope. To validate the eligibility of the desired antibodies a variety of drugs and metabolites sharing structural similarities to the individual drugs were tested for their cross-reactivity. It could be shown that only a few very closely related compounds exhibited substantial cross-reactivity. These monoclonal antibodies are therefore assumed to be suitable for a TDM-assay development.
Walter
G
G
Research Laboratories, Behringwerke AG, Marburg, W.-Germany.
Grün
K
K
Siebert
M
M
Bausch
S
S
Gassmann
S
S
Löchel
B
B
Kreider
R
R
Blackwood
J
J
Inbar
S
S
D000911:Antibodies, Monoclonal; D000927:Anticonvulsants / Q000097:blood*; D002220:Carbamazepine / Q000097:blood; D003429:Cross Reactions; D006801:Humans; D008991:Monitoring, Physiologic / Q000379:methods; D010634:Phenobarbital / Q000097:blood; D010672:Phenytoin / Q000097:blood; D011324:Primidone / Q000097:blood; D014635:Valproic Acid / Q000097:blood
D000911:Antibodies, Monoclonal; D000927:Anticonvulsants; D011324:Primidone; D002220:Carbamazepine; D014635:Valproic Acid; D010672:Phenytoin; D010634:Phenobarbital